Government attracts ₹5,210 crore pharma investment under PLI scheme

The Production Linked Incentive (PLI) scheme has emerged as a key driver of pharmaceutical sector growth, attracting significant capital commitments for bulk drug manufacturing up to June this year. Government figures show that the scheme has mobilised ₹5,210 crore in investments, reflecting growing investor confidence in India's ambitions to strengthen its position as a global pharmaceutical hub.

The PLI initiative focuses specifically on enhancing manufacturing capacity for active pharmaceutical ingredients (APIs), the critical raw materials that form the foundation of all drug production. By incentivising domestic production, the scheme aims to reduce India's reliance on imports and insulate the supply chain from external disruptions, a concern that gained prominence during global pandemic-related shortages.

Government officials have underscored the scheme's role in driving structural improvements across the pharma sector. The investments are expected to boost production efficiency, create manufacturing infrastructure, and generate employment within the industry. The capital deployment also reflects optimism about India's potential to capture a larger share of the global APIs market, currently dominated by a handful of countries.

The PLI scheme for bulk drugs forms part of a broader policy framework aimed at elevating India's pharmaceutical self-sufficiency. As geopolitical supply chain vulnerabilities persist, securing domestic capacity for critical pharmaceutical inputs has become a strategic priority for policymakers seeking to strengthen India's healthcare security and competitiveness.